A dietary composition and method for treating kidney damage and/or disease with a fasting-mimicking diet is provided. The method includes a step of identifying a subject having kidney damage. A low sodium fasting-mimicking diet with a specific dietary composition is administered to the subject for a first time period of 1 to 10 days.

Provided are methods for treating neuropathic pain by administering to a subject in need thereof a compound comprising phenyl-indole scaffold, wherein the compound has a modulatory effect on cannabinoid type 1 receptor (CB.sub.1R). Pharmaceutical compositions containing compounds comprising phenyl-indole scaffolds and pharmaceutically acceptable carriers are also provided, along with methods of using the same.

##STR00001##

##STR00002##

Provided are methods for treating neuropathic pain by administering to a subject in need thereof a compound comprising phenyl-indole scaffold, wherein the compound has a modulatory effect on cannabinoid type 1 receptor (CB.sub.1R). Pharmaceutical compositions containing compounds comprising phenyl-indole scaffolds and pharmaceutically acceptable carriers are also provided, along with methods of using the same.

##STR00001##

##STR00002##

Methods and compositions for preventing sympathetic activation resulting from administration of a TRPV1 modulator alone. Methods include co-administering QX-314 and a TRPV1 modulator to prevent sympathetic activation resulting from administration of a TRPV1 modulator alone comprising administering QX-314 and the TRPV1 modulator to a subject in need thereof. Compositions include a composition to prevent sympathetic activation comprising QX-314 and a TRPV1 modulator.

The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

The present invention provides methods for treating, preventing or ameliorating a fibrotic condition. The methods of the present invention include administering to a patient suffering from a fibrotic condition a therapeutically effective amount an anti-interleukin-36 receptor (anti-IL-36R) antibody.

The present invention provides methods for treating, preventing or ameliorating a fibrotic condition. The methods of the present invention include administering to a patient suffering from a fibrotic condition a therapeutically effective amount an anti-interleukin-36 receptor (anti-IL-36R) antibody.

A composition for mitigating, treating, and/or preventing symptoms associated with veisalgia. In one embodiment the composition comprises one or more ingredients selected from the group consisting of: dihydromyricetin, N-acetyl cysteine, salicin, quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, monk fruit, turmeric, curcumin, ginger root, and black pepper extract. A method for treating symptoms associated with veisalgia is also described. In one embodiment, the composition is administered in liquid or pill form.

Provided herein are methods and compositions for treating solid tumor cancers.

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.